Inclusion Criteria:

          -  Age ≥18 years

          -  Histologically-confirmed diagnosis of Follicular lymphoma (FL), mantle cell lymphoma
             (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic
             lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL), or AML

             a. Subjects must have disease that has relapsed or is refractory to 2 or more prior
             regimens and in need of treatment due to progressive disease

          -  Presence of measurable disease defined per the 2008 International workshop on CLL
             guidelines, or by 2014 Lugano criteria for non-Hodgkin lymphoma (does not apply for
             AML subjects)

          -  Adequate hematologic parameters unless clearly due to the disease under study

          -  Adequate renal and hepatic function, per laboratory reference range at screening

        Exclusion Criteria:

          -  History of pneumonitis of any cause

          -  For CLL subjects: only known histological transformation to an aggressive lymphoma

          -  For AML subjects:

               1. Acute promyelocytic leukemia

               2. Peripheral blast count > 25 × 10 9/L

          -  Known central nervous system involvement

          -  Significant cardiovascular disease

          -  Significant screening ECG abnormalities

          -  Subjects who require warfarin, anti-cancer therapeutics or investigational agents

          -  Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper
             respiratory tract infections) at the time of start of voruciclib therapy

          -  Prior solid organ transplantation

          -  Receipt of an allogeneic transplant within 6 months or an autologous transplant within
             the preceding 3 months; evidence of ongoing graft-versus-host disease (GVHD)

          -  Prior therapy with a cyclin-dependent kinase (CDK9) inhibitor

          -  Ongoing immunosuppressive treatment at the time of the start of voruciclib therapy,
             including systemic or enteric corticosteroids except as follows:

               1. Prior to the start of voruciclib therapy, subjects may be using systemic
                  corticosteroids (≤20 mg/day of prednisone or equivalent), topical, or inhaled
                  corticosteroids

               2. During study therapy, subjects may use systemic, topical, or enteric
                  corticosteroids, if needed